Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited
Jun 27, 2022
Read MoreZai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China
Jun 10, 2022
Read MoreZai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
Jun 03, 2022
Read MoreZai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference
May 31, 2022
Read MoreZai Lab Announces Change to Virtual 2022 Annual General Meeting of Shareholders to be Held on June 22, 2022
May 20, 2022
Read More